## **CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE — CIRI**

Centre International de Infectiologie

### UNDERSTANDING INFECTIOUS DISEASES TO BETTER CONTROL THEM

http://ciri.ens-lyon.fr

### **RESEARCH TOPICS**

- VIROLOGY
- BACTERIOLOGY
- IMMUNOLOGY
- EPIDEMIOLOGY AND ECO-INFECTIOLOGY

### **CROSS-CUTTING THEMES**

LESSONS FROM THE DIVERSITY OF CLINICAL AND ENVIRONMENTAL STRAINS

 CELLULAR BIOLOGY OF
INFECTIONS AND INNATE IMMUNITY

 HIGHLY PATHOGENIC
VIRUSES IN HUMANS AND THEIR NATURAL RESERVOIRS

INFLAMMATORY DISEASES

IMMUNOTHERAPY
AND VACCINATION



### **RESEARCH EQUIPMENT AND TOOLS**

- BioSafety Level 3 laboratories and main user of the BSL4 Jean Mérieux laboratory
- Shared platforms UAR Biosciences (PBES animal facility/AniRA, imaging/ cytometry, uectorology, etc.)
- EquipEx+ InfectioTron
- National Reference Centers: uiral hemorrhagic feuers, respiratory infections, staphylococci, legionella, etc.
- Study models: blood cells, mutant mice, humanized mouse

### **KEY FIGURES**

420	staff including <b>43</b> researchers, <b>83</b> professors and assitant professors including <b>58</b> medical professors and assistant professors, <b>17</b> hospital practitioners, <b>76</b> PhD students, <b>30</b> post-doctoral fellows and <b>130</b> research support staff
Ouer 2015-2020:	
More than 600	publications
25	prizes including: <b>1</b> Inserm Research Prize, <b>1</b> CNRS Bronze Medal, <b>2</b> Legions of Honor, <b>1</b> IUF
28	European funding (5 ERC as coordinator), <b>120</b> national funding type ANRt (60 as coordinator)
68	industrial contracts, <b>12</b> Cifre thesis, <b>3</b> public-private laboratories
80	intellectual properties: 27 patents filed, 13 licensed
TRL scale between 1 and 7-8	

## **CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE — CIRI**



# FOCUS ON

### Institutional partnership research

The RHU IdBIORIV (Hospital-University Research) is a transdisciplinary partnership between CIRI (StaPath Team directed by F Vandenesch), the Institute of Analytical Sciences and the Canadian company SCIEX.

It was founded as part of the national Investments for the Future program (PIA).

> Objective: to develop – based on a proteomic approach – a sepsis diagnostic tool that can, in less than 60 minutes, identify the pathogen, characterize its antibiotic resistance profile and level of virulence.

#### Private partnership research

The start-up VAXXEL is working to develop a new intranasal pediatric vaccine.

Originating from the VirPath team, led by B Lina and M Rosa-Calatrava, this startup was rewarded during the i-Lab 2019 competition.

 > Objective: to develop a vaccine directed against human metapneumovirus (hMPV) and respiratory syncytial virus (RSV), responsible for bronchiolitis and pneumonia, especially in infants.

Find out more: https://uaxxel.fr

## Collaboration between Boehringer Ingelheim and T Walzer LYACTS team

> **Objective:** to develop inhibitors of a molecule of the innate immune system, for the treatment of autoimmune and auto-inflammatory diseases.

#### FROM THE LABORATORY TO THE SOCIO-ECONOMIC WORLD

- Laboratory for basic and translational research in immunology and microbiology (bacteriology and uirology).
- Major player at the regional and/or national level in the diagnosis, prevention medicine and treatment of infectious and/or immune diseases.
- Strong roots in the local ecosystem interested in infectious diseases (HCL, VetAgroSup, Mérieux Foundation, Pasteur Institute, IRT BIOASTER, Lyonbiopôle, Sanofi, etc.)

#### CONTACT

CIRI – Inserm U1111, UMR 5308, Uniu Lyon 1 ENS de Lyon, Monod campus Director: François-Loïc Cosset Email: ciri@inserm.fr Telephone: +33 (0)4 37 28 23 60 http://ciri.ens-lyon.fr

🕆 Inserm







